PMCF (Post-Market Clinical Follow-Up) is a continuous, proactive process of collecting and evaluating clinical data on a CE-marked medical device after it reaches the market. Required by EU MDR 2017/745 Annex XIV Part B, it confirms a device’s safety and performance across its lifetime and feeds updated evidence back into the clinical evaluation.
What is PMCF (Post-Market Clinical Follow-Up)?
PMCF (Post-Market Clinical Follow-Up) is the clinical arm of a manufacturer’s post-market surveillance (PMS) system. Where PMS is largely reactive, capturing complaints, vigilance reports, and field data as they arrive, PMCF is deliberate: the manufacturer plans specific activities to keep generating clinical evidence once the device is in real-world use.
It sits at the tail end of the device lifecycle but never stops. Data gathered through PMCF updates the Clinical Evaluation Report (CER) and confirms that the benefit-risk profile established at CE marking still holds. EU MDR 2017/745 defines it in Annex XIV Part B, and two MDCG guidance documents, MDCG 2020-7 and MDCG 2020-8, provide the plan and report templates that Notified Bodies expect to see.
Why PMCF (Post-Market Clinical Follow-Up) matters in medical device development
Under the old Medical Device Directive, follow-up was often light. EU MDR changed that. For most devices, PMCF is now an explicit obligation, and a weak or missing plan is one of the more common Notified Body findings during MDR certification and surveillance audits.
The stakes are concrete. PMCF data flows into the Periodic Safety Update Report (PSUR) and the ongoing clinical evaluation, so gaps there ripple into your technical documentation. For Class III and implantable Class IIb devices, the PSUR is reviewed on a tight cadence, and thin clinical data can stall a certificate renewal.
There is also a design feedback loop. Real-world evidence surfaces rare complications, off-label use, and usability issues that pre-market studies miss, and catching them early protects patients. Ignore PMCF, and you risk audit findings, certificate suspension, and costly remediation once a problem is in the field.
How PMCF (Post-Market Clinical Follow-Up) works
The process runs as a documented cycle tied to your clinical evaluation:
- Write the PMCF Plan. Following the MDCG 2020-7 template, define the objectives, the specific data gaps carried over from the CER, the methods, and the timelines. Scope everything to the device’s risk class, novelty, and intended purpose.
- Run PMCF activities. These fall into two groups. General methods include structured user surveys, screening of scientific literature, and analysis of registry and real-world data. Specific methods include post-market clinical investigations conducted to ISO 14155:2026, the current edition of the good clinical practice standard for device studies.
- Analyze and report. Findings are compiled in a PMCF Evaluation Report using the MDCG 2020-8 template.
- Feed the results back. Conclusions update the CER, the PSUR, and, where warranted, the risk management file under ISO 14971 and the instructions for use.
Several standards and clauses govern the work. Articles 83 to 86 of the EU MDR set the PMS framework that PMCF lives inside; Annex XIV Part B sets the PMCF requirements; ISO 14155:2026 governs any post-market clinical investigation. Note a recent wrinkle: EN ISO 14155:2020/A11:2024 was harmonized under MDR in January 2026 through Implementing Decision (EU) 2026/193, and the fourth edition (ISO 14155:2026) then superseded it with almost no transition period.
Common challenges and best practices
The most frequent mistake is treating PMCF as a checkbox. A generic satisfaction survey with no link to the actual CER data gaps produces low-value evidence that Notified Bodies discount. Another is timing: teams write the plan, then let activities and report updates drift out of sync with the PSUR cycle.
Good practice starts with the CER. Map each PMCF objective to a specific unresolved question about safety, performance, or long-term outcomes. Choose methods proportionate to risk, so a low-risk reusable instrument does not carry the same evidence burden as a novel implant. Define measurable endpoints up front, set a realistic data-collection cadence, and confirm that survey instruments are validated for the claim you are trying to support. For higher-risk devices, plan for prospective, multi-site data collection early, since registries and observational studies take time to accrue meaningful numbers.
How SJML helps with PMCF (Post-Market Clinical Follow-Up)
SJML’s Compliance-as-a-Service team supports the full post-market clinical pathway. That includes PMS and PMCF planning, clinical evaluation work (CEP, CER, and literature review), PSUR and PMSR preparation, and vigilance and complaints handling with root-cause analysis and CAPA. The same team maintains the surrounding regulatory files, from ISO 13485 and MDSAP quality systems to ISO 14971 risk management and EUDAMED activities, so PMCF outputs connect cleanly to your technical documentation rather than sitting in isolation. Engagements scale from a single plan to managed, ongoing QARA support for startups and established OEMs alike.
Frequently asked questions
For most devices, yes. EU MDR 2017/745 Annex XIV Part B requires manufacturers to conduct PMCF as part of their post-market surveillance system. A manufacturer may justify not performing PMCF, but that justification must be documented and accepted by the Notified Body. In practice, higher-risk and implantable devices almost always require an active PMCF plan.
Post-market surveillance (PMS) is the broad system for monitoring a device once it is on the market, including complaints, vigilance, and field data. PMCF is the specifically clinical, proactive part of that system. PMS often reacts to incoming signals, while PMCF plans structured activities to generate new clinical evidence and confirm long-term safety and performance.
Valid methods include structured user surveys, screening of published scientific literature, participation in device or implant registries, analysis of real-world data, and prospective post-market clinical investigations run to ISO 14155:2026. The right mix depends on the device’s risk class, novelty, and the specific data gaps identified in the Clinical Evaluation Report. Methods should be proportionate, not maximal.
Cadence follows device class. For Class III and implantable Class IIb devices, the clinical evidence and PSUR are typically reviewed annually. Lower-risk devices are usually updated on a two- to five-year cycle, or sooner if PMS data raises a new safety or performance question. The PMCF Evaluation Report follows the MDCG 2020-8 template.
Related terms
- Post-Market Surveillance (PMS)
- Clinical Evaluation Report (CER)
- Periodic Safety Update Report (PSUR)
- Vigilance and FSCA
- ISO 14155
